

Febuxostat prevents gout flares in recent clinical trial

4 October 2017

As reported in the journal *Arthritis & Rheumatology*, the drug febuxostat reduced gout flares in a double-blind, placebo-controlled study of 314 adults with early gout. Febuxostat treatment also reduced synovitis—or inflammation of the joint lining detected by MRI scanning—over a 2-year period compared with placebo.

Febuxostat treats high urate in the blood of patients with [gout](#).

"Current clinical practice guidelines do not recommend routine use of urate-lowering therapy for people after the first gout flare. This study indicates that even for people who have had only 1 or 2 prior gout flares, urate-lowering therapy to reduce serum urate below 6mg/dL may have benefit in reducing future flares," said Dr. Nicola Dalbeth, lead author of the study.

More information: *Arthritis & Rheumatology*,
[DOI: 10.1002/art.40233](https://doi.org/10.1002/art.40233)

Provided by Wiley

APA citation: Febuxostat prevents gout flares in recent clinical trial (2017, October 4) retrieved 27 June 2019 from <https://medicalxpress.com/news/2017-10-febuxostat-gout-flares-clinical-trial.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.